La cadena de opciones muestra datos clave de las opciones de acciones de Microvast Holdings a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Microvast Holdings..

Microvast Holdings (NASDAQ:MVST) Bolsa, Cadena de Opciones

Microvast Holdings

Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wolfe Research analyst Bill Carcache downgraded the rating for The PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) from Outperform to Peer Perform. PNC Financial shares closed at $195.70 on Wednesday. <a href="https://www.benzinga.com/quote/PNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Justin Walsh downgraded the rating for Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) from Buy to Hold. Theratechnologies shares closed at $2.36 on Wednesday. <a href="https://www.benzinga.com/quote/THTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Trevor Cranston downgraded Two Harbors Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWO#NYSE">TWO</a>) from Market Outperform to Market Perform. Two Harbors Investment shares closed at $10.65 on Wednesday. <a href="https://www.benzinga.com/quote/TWO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Maxim Group analyst Tate Sullivan downgraded the rating for NV5 Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) from Buy to Hold. NV5 Global shares closed at $23.22 on Wednesday. <a href="https://www.benzinga.com/quote/NVEE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PNC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PNC/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-1024x595.png" alt="" class="wp-image-972162" style="width:509px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094948/image-44.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

NVEE

THTX

This PNC Financial Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

UBS analyst Joshua Chan maintains UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Neutral and lowers the price target from $196 to $194.

Price Target

UBS Maintains Neutral on UniFirst, Lowers Price Target to $194

Loop Capital analyst Jeffrey Stevenson maintains BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) with a Buy and lowers the price target from $21 to $20.

Loop Capital Maintains Buy on BrightView Hldgs, Lowers Price Target to $20

UBS analyst Peter Grom maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Buy and raises the price target from $195 to $205.

UBS Maintains Buy on Constellation Brands, Raises Price Target to $205

Macro Economic Events

Econ #s

Economics

S&P Global Composite PMI For June 52.9 Vs 52.8 Est.

Macro Notification

General

S&P Global Services PMI For June 52.9 Vs 53.1 Est.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Tim Rezvan initiated coverage on Prairie Operating Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) with a Sector Weight rating. Prairie Operating shares closed at $3.44 on Wednesday. <a href="https://www.benzinga.com/quote/prop/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Robert Burns initiated coverage on Telix Pharmaceuticals Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announced a price target of $23. Telix Pharmaceuticals shares closed at $16.42 on Wednesday. <a href="https://www.benzinga.com/quote/tlx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Sean Milligan initiated coverage on Primoris Services Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) with a Buy rating and announced a price target of $102. Primoris Services shares closed at $82.00 on Wednesday. <a href="https://www.benzinga.com/quote/prim/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Ridley-Lane initiated coverage on Ralliant Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RAL#NYSE">RAL</a>) with an Underperform rating and announced a price target of $48. Ralliant shares closed at $45.77 on Wednesday. <a href="https://www.benzinga.com/quote/ral/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying PRIM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-1024x574.png" alt="" class="wp-image-972152" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03094158/image-43.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a> </li>
</ul>
Photo via Shutterstock

Initiation

PRIM

PROP

This Primoris Services Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday

Citigroup analyst Ronald Josey maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Neutral and lowers the price target from $40 to $37.

CARG

Citigroup Maintains Neutral on CarGurus, Lowers Price Target to $37

<a href="https://truthsocial.com/@realDonaldTrump/114789577865630441">https://truthsocial.com/@realDonaldTrump/114789577865630441</a>

Politics

President Trump Posts On Truth Social "Will be speaking to President Putin of Russia at 10:00 A.M. Thank you!"

- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY&#xAE; -
- Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -
TORONTO, July 3, 2025 /CNW/ - <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4462066-1&amp;h=2284321717&amp;u=https%3A%2F%2Fwww.vrtx.ca%2F&amp;a=Vertex+Pharmaceuticals">Vertex Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) recently announced positive longer-term data for PrCASGEVY&#xAE; (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people&nbsp;with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress,&nbsp;continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy.

Biotech

VRTX

Vertex's CASGEVY Shows Over 5.5 Years Of Durable Benefit In Sickle Cell And Beta Thalassemia Trials Presented At The EHA Congress; Multiple Reimbursement Agreements Secured

Citigroup analyst Filippo Falorni maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Neutral and raises the price target from $170 to $174.

Citigroup Maintains Neutral on Constellation Brands, Raises Price Target to $174

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">least four prior lines of therapy</a>.
Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46223573/lynozyfic-linvoseltamab-gcpt-receives-fda-accelerated-approval-for-treatment-of-relapsed-or-refrac" rel="noreferrer noopener">benefit in a confirmatory trial</a>.
Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45755748/johnson-johnson-highlights-multiple-blood-cancer-trial-data-at-asco-presentation" rel="noreferrer noopener">Johnson &amp; Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation</a>
The regimen includes hospitalization for safety during the step-up dosing period (one 24-hour period after the first step-up dose, and another 24 hours after the second step-up dose).
The FDA approval for linvoseltamab in R/R MM is based on the pivotal Phase 1/2 LINKER-MM1 trial. In this trial, patients (n=80) experienced a 70% objective response rate (ORR), with 45% achieving a complete response (CR) or better.
The median time to first response was 0.95 months. The median duration of response (DoR) was not reached. Among responders, the estimated DoR was 89% at 9 months and 72% at 12 months, with a median follow-up of 13 months.
The prescribing information for Lynozyfic includes a Boxed Warning for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, in addition to warnings and precautions for infections, neutropenia, hepatotoxicity, and embryo-fetal toxicity.
In other news for the company, and highlighting their broader portfolio of approved treatments, in June, the FDA approved Regeneron and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46028780/fda-approves-regeneronm-sanofi-treatment-for-rare-autoimmune-skin-disorder" rel="noreferrer noopener">autoimmune skin disorder</a>.
BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46019439/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-with-bullou" rel="noreferrer noopener">underlying type 2 inflammation</a>.
Price Action: REGN stock is trading higher by 0.24% to 549.06 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46242132/crwd-stock-could-soar-16-says-wedbushs-dan-ives-coming-in-very-strong-with-healthy-momentum" target="_blank" rel="noreferrer noopener">CRWD Stock Could Soar 16%, Says Wedbush&#8217;s Dan Ives: &#8216;Coming In Very Strong With Healthy Momentum&#8217;</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Large Cap

Health Care

REGN

Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Laura Martin upgraded the rating for Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) from Underperform to Hold. Meta shares closed at $713.57 on Wednesday. <a href="https://www.benzinga.com/quote/meta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Bill Carcache upgraded the rating for Huntington Bancshares Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) from Peer Perform to Outperform. Huntington Bancshares shares closed at $17.40 on Wednesday. <a href="https://www.benzinga.com/quote/hban/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/meta/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-1024x597.png" alt="" class="wp-image-972142" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/03093313/image-42.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46218519/jim-cramer-gives-utilities-stock-a-week-says-doge-not-done-clobbering-booz-allen">Jim Cramer Gives Utilities Stock &#8216;A Week,&#8217; Says DOGE &#8216;Not Done Clobbering&#8217; Booz Allen</a></li>
</ul>
Photo via Shutterstock

Upgrades

HBAN

This Meta Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Thursday

BGLWW

Blue Gold Partners With TripleBolt Technology To Explore Possible Development Of Blockchain-Based Digital Asset Backed By Gold Futures

AGRO

Adecoagro And Tether Sign MoU To Explore Strategic Collaboration Focused On Bitcoin Mining

Citigroup analyst Christopher Allen maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Neutral and raises the price target from $265 to $275.

Citigroup Maintains Neutral on CME Group, Raises Price Target to $275

WIIM

ReNew Energy Global shares are trading higher after Canada Pension Plan Investment boosted its stake in the company to 34.6% and submitted an $8.00 per share non-binding takeover proposal with consortium. Also, Abu Dhabi Investment authority-led consortium raised its offer to acquire the company for $8.00 per share.

Citigroup analyst Anthony Pettinari maintains O-I Glass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) with a Neutral and raises the price target from $14 to $16.

Citigroup Maintains Neutral on O-I Glass, Raises Price Target to $16

Institutions Subscribe at US$10.45 per ADS, Demonstrating Strong Investor Confidence
SINGAPORE, July 3, 2025 /PRNewswire/ -- Amber International Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBR#NASDAQ">AMBR</a>) ("Amber International", or the "Company"), a leading provider of institutional crypto financial services &amp; solutions and operating under the brand name "Amber Premium", today announced continued progress on its $100 million Crypto Ecosystem Reserve Strategy, enhanced by proceeds from a recently announced $25.5 million private placement.
Participating institutional investors subscribed at a price of US$10.45 per American Depositary Share (ADS), determined based on a 5% discount to the 3-day volume-weighted average price (VWAP) of AMBR's ADSs on Nasdaq between June 25 and June 27, 2025. This corresponds to US$2.09 per Class A ordinary share, based on the 5:1 ratio of Class A ordinary shares to ADSs. The private placement involved the issuance of 12,200,915 Class A ordinary shares—equivalent to 2,440,183 ADSs—and was supported by a distinguished group of institutional investors including CMAG Funds, Mile Green, Pantera Capital, Choco Up, Kingkey Financial International (Holdings) Limited (1468.HK), and other prominent investors.
Proceeds from the private placement will be strategically used to enhance Amber International's $100 million Crypto Reserve initiative, which is designed to support long-term ecosystem alignment and product innovation. Since the strategy's announcement earlier this year, the reserve has been allocated toward major digital assets including Bitcoin (BTC), Ethereum (ETH), and Solana (SOL), with ongoing deployment into Binance Coin (BNB), Ripple (XRP), and Sui (SUI).

AMBR

Amber International Advances $100M Crypto Ecosystem Reserve Strategy Bolstered By Proceeds From Recent $25.5M Private Placement

July 2, 2025
&nbsp;
VIA E-MAIL
ReNew Energy Global plc
Special Committee of the Board of Directors
C/O Vistra (UK) Ltd
Suite 3, 7th Floor, 50, Broadway,
London, England, SW1H 0DB
Attention: Mr. Manoj Singh, Lead Independent Director
Dear Manoj:
The consortium is pleased to confirm its continued interest in the transaction and would like to thank you, the rest of the special committee and the management of the company, for your time and continued engagement. The consortium would like to take this opportunity to outline where it stands in its evaluation of the transaction, including with regards to value. Subject to alignment on the points outlined below, the consortium sees a clear path to a mutually agreeable transaction on an expedient timeline.
&nbsp;
Revised Proposal
With your support, the consortium has undertaken comprehensive due diligence (including, but not limited to, technical, commercial, financial, tax, legal and other due diligence), underscoring its significant investment of resources in this transaction. Our due diligence investigation has allowed us to assess the performance of the company and its outlook and refine&nbsp;our view on valuation. On that basis, the consortium is prepared to increase its offer price to US$8.00 per share, payable in cash, for the entire issued and to be issued share capital of the company not already owned by the members of the consortium.
Our revised proposal would provide the company's shareholders with a 26% premium to the closing share price of $6.34 per share on December 10, 2024 and a 39% premium to the 30-day volume-weighted average price of $5.76 per share (as of December 10, 2024).
The consortium believes that its revised proposal, which would provide shareholders with immediate liquidity and value certainty not available in public markets, would be in the best interest of the company and its shareholders, and the consortium trusts that it bears evidence of its willingness to take the transaction forward. The revised proposal is based on the information that you have made available to us and reflects the findings of our due diligence. The revised proposal is a final non-binding offer.
&nbsp;
Definitive Documentation
We have already circulated a draft transaction agreement to the Linklaters team. We look forward to engaging with the special committee on it, in order to finalize it as soon as possible.
Due Diligence
The consortium's remaining due diligence is purely confirmatory in nature and key pending areas have been outlined to the special committee. The consortium's financial advisors will also reach out separately to highlight the specific remaining confirmatory items.
&nbsp;
Shareholder Support
The consortium expects the special committee, its advisors and the company to engage with top shareholders to ensure their support of the transaction. In addition, the consortium expects the special committee, its advisors and the company to deliver hard irrevocable commitments from certain major shareholders and from directors (other than the founder and the nominee directors of the consortium members) prior to the announcement of any binding transaction.
Pre-Signing Approvals
Once transaction documents are in near final form, the consortium will seek internal approvals to be able to sign and expects that these approvals can be obtained within three weeks of the transaction documents being finalised.

Comments

Microvast Holdings

Microvast Holdings (MVST) Opciones

Microvast Holdings (NASDAQ:MVST) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL